No product was tested by this publication, and no clinical claim made by the brand was independently verified beyond confirming that the brand itself makes the claim
However, many epidemiologic studies fail to account for the intentionality of weight loss
Studies have evaluated once-weekly subcutaneous retatrutide at doses including 1 mg, 4 mg, 8 mg, 9 mg, and 12 mg, depending on the trial and target population [4], [5], [6], [7], [9]
Other factors that may influence side effect experience include baseline gastrointestinal health, concurrent medications, dietary habits, hydration status, rate of dose escalation, and individual sensitivity to GLP-1 receptor activation
With so many weight loss medications available from Novo Nordisk's Ozempic and Wegovy to Eli Lilly's Mounjaro and Zepbound it can be tough to compare prices, coverage, and side effects
Muscogiuri G, Barrea L, Annunziata G, et al